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Abstracts / Urological Science 27 (2016) S1eS23 S3Conclusion: High HK2 expression in bladder cancers induced over-
secretion of lactate, which was associated with metastatic behaviors
through the cancer stem cell formation, EMT promotion and nuclear
translocation of phosphorylated NF-kB and Twist1. HK2 may be a novel
oncoprotein and play as target for bladder cancer therapy.
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Purpose: According to our previous results in methylated-CpG island re-
covery assay (MIRA) and RNA expression array, methylated status of
Interferon regulatory factor 6 (IRF6) could be observed in most of renal cell
carcinoma (RCC) cases, and presented a negative correlation with gene
expression, especially in clear cell type of RCCs. The aim of this study is to
clarify the clinical signiﬁcance and role of IRF6 in RCC.
Materials and Methods: 105 pairs of clinical RCC patients and RCC cell
lines have involved in the current study. Real-time PCR assay was used to
detect the expression of IRF6 on all cases. Western blot assay was per-
formed to detect whether the expression of IRF6 in the 5-aza-2'deoxy-
cytidine treated RCC cells could be restored. The IRF6 gene expression level
in normal and RCC tissues were shown byeDCT and applied by the paired-
T test.
Results: The variant and lower level gene expression of the IRF6 could be
observed in most of RCC cell lines. After cells treated with 5-aza-2'deox-
ycytidine, the expression of IRF6 was restored. In the real-time PCR of IRF6
in RCC tissues, the mean eDCT was 8.0 in normal tissue and 11.5 in RCC
tissue with signiﬁcantly different (P¼ 0.013).
Conclusion: Our ﬁndings demonstrated that the aberrant expression of
IRF6 in RCCs was due to methylation. Also, the expression level of IRF6 was
higher in normal tissues as compared with tumor tissues. Besides, it has
been described that IRF6 could function as a tumor suppressor since it
could inhibit tumor invasion and migration in squamous cell carcinoma.
Based on these results, we suggest that IRF6 may play an important role in
the pathophysiology of RCC. However, further cell viability and correlation
with the clinical information should be further analyzed in the future.
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Purpose: Cisplatin has been used to treat bladder cancer (BC), however,
cisplatin alone is not very effective, and the combinations of gemcitabine/
cisplatin is now the ﬁrst-line chemotherapy. Moreover, bladder tumor
exhibits high basal level of autophagy. In this study, we investigated if
cisplatin induces more autophagy in human BC cells, and whether inhi-
bition of cisplatin-induced autophagy enhances apoptosis that leads to
cancer cell death.
Materials and Methods: The autophagy status in cisplatin-treated RT4
(grade I), 5637 (grade II), and T24 (grade III) human bladder cancer cells
was performed by the detection of microtubule-associated light chain 3
form II (LC3-II) and aggregation of LC3 puncta using Western blots and
immunoﬂuorescent staining, respectively. Moreover, the formation ofautophagolysosome was detected using transmission electron microscopy
to conﬁrm the increased number of autophagosomes in cisplatin-treated
T24 cells. The cell viability in cells treated with cisplatin with or without
the autophagy inhibitor, baﬁlomycin A1 (BafA1), was accessed by WST-1
cell viability kit. To investigate the signaling pathway involved in cisplatin-
induced autophagy, the activation of AKT, ERK, AMPK and MAPK and the
inhibition of mTOR in cisplatin-treated cells were detected by Western
blot. Induced apoptosis was determined by the detection of cleaved cas-
pase 3, cleaved PARP, the caspase 3/7 activity and the level DNA frag-
mentation in treated-cells.
Results: The processing of LC3-II was elevated in cells treated with
increased concentration of cisplatin, suggesting cisplatin induces auto-
phagy. Detection of autophagy ﬂux (by blocking autophgosome to lyso-
somes fusion using Baf A1) in 5637 and T24 cells, and the direct
observation of autophagolysosome formation in cisplatin-treated T24 cells
using TEM further conﬁrmed that cisplatin indeed triggers autophagy.
Advanced bladder cancer cells (5637 and T24) were more resistant to
cisplatin than RT4, suggesting autophagy acts as a survival mechanism in
high grade BC cells. While no response was found in AMPK, the activation
of AKT, ERK and MAPK signaling and inhibition of mTOR was detected in
cisplatin treated cells. However, pretreatment of speciﬁc inhibitors of ERK,
MAPK did not attenuated cisplatin-induced autophagy suggests these
pathways are not involved in the induction of autophagy. Finally, reduced
cell viability and induced apoptosis were detected in cisplatin-treated cells
pretreated with autophagy inhibitor suggesting that inhibition of auto-
phagy enhances cancer killing effect of cisplatin in human BC cells.
Conclusion: Cisplatin induces autophagy in human BC cells, and auto-
phagy inhibition enhances apoptosis in cisplatin-treated cells. This study
suggests a new therapeutic paradigm for the treatment of bladder cancer.
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Purpose: Autophagy is activated and may contributed to cisplatin-resis-
tance in cisplatin-treated bladder cancer (BC) cells. It is reasonable to
speculate that Inhibition of autophagy enhances the anti-cancer effects of
cisplatin in BC cells. In this study, we characterized the role of miR-30a-5p,
which is down-regulated in BC cells, in the coordination of apoptosis and
autophagy by accessing its potential targeting protein, ATG5 and beclin-1
(BECN1).
Materials and Methods: The BC cell lines, 5637 (grade II) and T24 (grade
III) and immortalized human uroepithelium cells (SV-HUC-1) were used in
this study. To elevate the expression level of miR-30a-5p, a small RNA
expression vector bearing matured sequence of miR-30a-5p (pSM-30a)
was constructed and transfected into human BC cells. The expression level
of miR-30a-5p was detected by stem-loop miRNA qPCR. Protein level of
ATG5 and BECN1, both are predicted targets of miR-30a-5p, was accessed
by Western blot. Autophagy detection in cisplatin-treated cells was per-
formed by monitoring LC3-II processing by Western blot. Induction of
apoptosis in cisplatin-treated cells with or without the over-expressed
miR-30a-5p was detected by the detection of cleaved caspase-3 and PARP.
Results: The expression level of miR-30a-5p was elevated up to 8 fold in
pSM-30a transfected BC cells according to miRNA qPCR. The autophagy
activity in BC cells increased after cisplatin treatment as indicated by the
enhanced processing of LC3-II. As ATG5 and BECN1 were predicted targets
for miR-30a-5p by TargetScan, forced expression of miR-30a-5p signiﬁ-
cantly reduced the expression level of ATG5, BECN1 and LC3-II induced by
cisplatin. The blockage of autophagy by miR-30a-5p expression or baﬁlo-
mycin A1 (Baf A1) signiﬁcantly decreased cell viability and increased
apoptosis in cisplatin-treated BC cells.
Abstracts / Urological Science 27 (2016) S1eS23S4Conclusion: Our results demonstrate that miR-30a-5p can sensitize BC
cells to cisplatin via suppressing ATG5 and BECN1 expression, therefore,
increasing miR-30a-5p level in BC represents a novel strategy to enhance
the efﬁcacy of cisplatin therapy during cancer treatment.
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Purpose: Increased urinary tract malignancy has been reported in end-
stage renal disease (ESRD). However, little is known about chronic kidney
disease (CKD). This study is designed to explore the association between
CKD and upper tract urothelial carcinoma (UTUC).
Materials and Methods: Using Taiwan's Longitudinal Health Insurance
Database, we studied CKD patients between January 2000 and December
2011. The non-CKD controls were selected at a ratio of 4:1 and frequency
matched by gender, age group and index date.We used Chi-square test and
t-test to analyze the sociodemographic information and comorbidities.
Cox regression analysis was used to calculate the hazard ratio (HR) and 95%
conﬁdence interval (CI).
Results: The selected cases included 45,321 CKD cases and 181,284 con-
trols. A signiﬁcantly higher incidence of UTUC was noted in the CKD group
(0.22% vs. 0.07%, p< 0.001). In univariate analysis, CKD, female gender, age,
hypertension, hematuria, repeated urinary tract infection, bladder cancer
and ESRD were all associated with UTUC. In multivariate analysis, only
CKD, female gender, age, hematuria, bladder cancer and ESRD were
signiﬁcantly associated. The HR for CKD was 1.63 (95% CI: 1.26e2.13). Fe-
males had a higher HR of 1.38 (95% CI: 1.11e1.71). After excluding those
patients who progressed to dialysis or kidney transplantation, the risk for
CKD was still high, with a HR of 1.72 (95% CI: 1.33e2.33).
Conclusion: CKD is a signiﬁcant factor associated with UTUC. We should
pay attention to the possibility of UTUC for CKD patients before they
progress to ESRD.
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Purpose: We propose a formula of calculate-based contact surface area
(CSA). We examined the correlation of contact surface area and renal
volume loss and the predictability for renal function after partial
nephrectomy.
Materials and Methods: We conducted a retrospective study in pa-
tients who underwent partial nephrectomy between January 2012 and
December 2014. Based on abdominopelvic CT and MRI, we calculated
the contact surface area with the formula “2* p *Radius*Depth”; while
resected and ischemic volume (RAIV) was determined by the equation”
[2w 2^+3w(r+d)+6rd]*w*p)⁄3”. We evaluated the correlation between
CSA, RAIV and perioperative parameters. And we comparatively
analyzed the ability of CSA and RAIV to predict the reduction in renal
function.
Results: There were 35, 26, and 45 patients receiving OPN, LPN, RPN
respectively. The mean±SD contact surface area was 30.7±26.1 cm2, and
and the mean±SD RAIV was 19.1±14.4 cm3. On Spearman correlation
analysis we found that CSA and RAIV were highly correlated (coefﬁ-
cient: 0.99, p < 0.001). In univariate analysis, BMI (p¼ 0.02), EBL(p¼ 0.001), RAIV (p < 0.001), and CSA (p < 0.001) signiﬁcantly affected
postoperative renal function. In ROC curve analysis, both CSA and RAIV
have good ability to predict more than 10% change of estimated
glomerular ﬁltration rate (AUC: 0.86 vs. 0.87). There is no signiﬁcant
difference in AUC between CSA and RAIV. The area difference in PCE10
was 0.002 (p¼ 0.51).
Conclusion: In our study, CSA and RAIV were correlated with several
perioperative outcomes and affected post-operative renal function. The
ability to predict post-operative renal function between CSA and RAIV was
nearly identical. Since CSA was simpler to use, and may possess less
interobserver variability in comparison with RAIV, we believe that CSA can
represent renal parenchymal loss.
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Purpose: Urothelial carcinomas (UCs) involve recurrent chromosome 9p
deletions. Methylthioadenosine phosphorylase (MTAP) on 9p21.3is a pro-
posed functional tumor suppressor gene. The role of MTAP in upper tract
UC (UTUC) is unknown. We aimed to investigate MTAP's association with
disease characteristics and oncologic outcomes in UTUC patients under-
going radical nephroureterectomy (RNU).
Materials and Methods: Using immunohistochemistry, we investigated
MTAP expression in 340 UTUC patients treated with RNU from1996e2004,
and correlated it with clinicopathologic characteristics and clinical out-
comes. Univariate and multivariate Cox regression analyses evaluated the
association of MTAP expression with disease-speciﬁc survival (DSS) and
metastasis-free survival (MeFS).
Results:MTAP was deﬁcient in 119 (35.0%) patients. MTAP deﬁciency was
signiﬁcantly associated with higher pathologic stage (p< 0.001), lymph
node metastasis (p< 0.001), high grade (p¼ 0.008), vascular invasion
(p¼ 0.001), perineural invasion (p¼ 0.001), and higher mitotic rate
(p¼ 0.016).Sixty (17.6%) patients died of UTUC and 70 (20.6%) developed
metastasis. MTAP-deﬁcient patients demonstrated signiﬁcantly worse DSS
(58.1% vs.89.3%; p< 0.0001) and MeFS (54.7% vs.87.9%; p< 0.0001) at ﬁve
years than those with intact expression. MTAP deﬁciency was indepen-
dently associated with cancer-speciﬁc mortality (hazard ratio [HR]:2.213,
p¼ 0.019; 95% conﬁdence interval [CI]:1.141e4.293) and metastasis
development (HR:2.867, p< 0.001; 95% CI:1.601e5.106).
Conclusion: MTAP deﬁciency is associated with aggressive cancer
phenotype and unfavorable oncologic outcomes, suggesting it may be a
new biomarker and provide additional prognostic information in UTUC
patients undergoing RNU.
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